Show simple item record

dc.contributor.authorda Rocha, Jorge E B
dc.contributor.authorOthman, Houcemeddine
dc.contributor.authorTiemessen, Caroline T
dc.contributor.authorBotha, Gerrit
dc.contributor.authorRamsay, Michèle
dc.contributor.authorMasimirembwa, Collen
dc.contributor.authorAdebamowo, Clement
dc.contributor.authorChoudhury, Ananyo
dc.contributor.authorBrandenburg, Jean-Tristan
dc.contributor.authorMatshaba, Mogomotsi
dc.contributor.authorSimo, Gustave
dc.contributor.authorGamo, Francisco-Javier
dc.contributor.authorHazelhurst, Scott
dc.date.accessioned2021-08-16T18:43:13Z
dc.date.available2021-08-16T18:43:13Z
dc.date.issued2021-07-23
dc.identifier.urihttp://hdl.handle.net/10713/16394
dc.description.abstractChloroquine/hydroxychloroquine have been proposed as potential treatments for COVID-19. These drugs have warning labels for use in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Analysis of whole genome sequence data of 458 individuals from sub-Saharan Africa showed significant G6PD variation across the continent. We identified nine variants, of which four are potentially deleterious to G6PD function, and one (rs1050828) that is known to cause G6PD deficiency. We supplemented data for the rs1050828 variant with genotype array data from over 11,000 Africans. Although this variant is common in Africans overall, large allele frequency differences exist between sub-populations. African sub-populations in the same country can show significant differences in allele frequency (e.g. 16.0% in Tsonga vs 0.8% in Xhosa, both in South Africa, p = 2.4 × 10-3). The high prevalence of variants in the G6PD gene found in this analysis suggests that it may be a significant interaction factor in clinical trials of chloroquine and hydroxychloroquine for treatment of COVID-19 in Africans.en_US
dc.description.urihttps://doi.org/10.1038/s41397-021-00242-8en_US
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.relation.ispartofPharmacogenomics Journalen_US
dc.rights© 2021. The Author(s).en_US
dc.subject.meshClinical Trials as Topicen_US
dc.subject.meshChloroquine--adverse effectsen_US
dc.subject.meshCOVID-19en_US
dc.subject.meshGlucosephosphate Dehydrogenase Deficiency--geneticsen_US
dc.subject.meshHydroxychloroquine--adverse effectsen_US
dc.subject.meshAfrica South of the Saharaen_US
dc.titleG6PD distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19en_US
dc.typeArticleen_US
dc.identifier.doi10.1038/s41397-021-00242-8
dc.identifier.pmid34302047
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record